CJC Ipa Rx

Sources

CJC-1295 Ipamorelin References: The Peer-Reviewed Record

Every quantitative claim in this digest maps to a numbered source below, with DOI and PubMed links.

About these sources

These are the peer-reviewed studies behind every CJC-1295 Ipamorelin claim on this site. They span the human pharmacokinetics of CJC-1295 (DAC), ipamorelin's selectivity, the foundational GHRH-plus-GHRP synergy work, the DAC bioconjugation chemistry, the ipamorelin bone-growth series, the GH-secretagogue safety synthesis, and the broader ghrelin-agonist class literature. Each source is listed with authors, journal, year, DOI, and a PubMed or DOI link. The numbering matches the inline citation markers used throughout the digest. Note the recurring caveat embedded in this list: none of these studies tested the fixed CJC-1295 Ipamorelin combination itself — the combination's rationale is assembled from each component's own record plus the general synergy literature.

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. ↗
  3. Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. ↗
  4. Cunha SR, et al. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-4582. ↗
  5. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  6. Sigalos JT, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. ↗
  7. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. ↗
  8. Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. ↗
  9. Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-272. ↗
  10. Svensson J, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. ↗
  11. Welle S, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis. Growth Horm IGF Res. 2009;19(3):260-265. ↗
  12. Camilleri M, et al. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol. 2009;6(6):343-352. ↗
  13. Fraser GL, et al. Effect of the ghrelin receptor agonist TZP-101 on colonic transit in a rat model of postoperative ileus. Eur J Pharmacol. 2009;604(1-3):132-137. ↗
  14. Mendias CL, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗